Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Clecell Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This involves 1 distinct examiner and 1 distinct art unit. ABEYRATNE-PERERA, HASHANTHI KOMITIGE is the busiest examiner, with 1 busiest examiner pending action. The prosecution is currently focused on 1 distinct examiner within 1 distinct art unit.
This concentration in the Biotechnology & Pharmaceuticals sector suggests a specific technical focus for the current 1 pending office action. Having 1 distinct examiner, ABEYRATNE-PERERA, HASHANTHI KOMITIGE, allows the applicant to develop a consistent strategy for this matter. The 1 pending office action represents the entirety of the company's current active prosecution. With only 1 distinct art unit involved, the technical scope is likely very specific. The fact that ABEYRATNE-PERERA, HASHANTHI KOMITIGE holds 1 busiest examiner pending action confirms that there is no examiner diversity in the current workload. This streamlined profile makes it easier for the company to monitor and respond to patent office communications.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABEYRATNE-PERERA, HASHANTHI KOMITIGE | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18280218 | MANUFACTURING DEVICE OF ARTIFICIAL SKIN USING CELLS DIFFERENTIATED FROM INDUCED PLURIPOTENT STEM CELLS | ABEYRATNE-PERERA, HASHANTHI KOMITIGE | 40d |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18280218 | MANUFACTURING DEVICE OF ARTIFICIAL SKIN USING CELLS DIFFERENTIATED FROM INDUCED PLURIPOTENT STEM CELLS | ABEYRATNE-PERERA, HASHANTHI KOMITIGE | 1632 | §102§112 | Non-Final OA | 40d | Pending | Sep 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial